NRX Pharmaceuticals Q1 2025: Minimal Revenue, Significant Cash

Ticker: NRXPW · Form: 10-Q · Filed: May 15, 2025 · CIK: 1719406

Nrx Pharmaceuticals, INC. 10-Q Filing Summary
FieldDetail
CompanyNrx Pharmaceuticals, INC. (NRXPW)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

NRXP Q1 2025: $0 revenue, $17.1M cash. Still burning cash.

AI Summary

NRX Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported $0.001 in revenue for the quarter. As of March 31, 2025, NRX Pharmaceuticals had $17,120,120 in cash and cash equivalents, and total assets of $14,591,505.

Why It Matters

This filing provides a snapshot of NRX Pharmaceuticals' financial health at the end of Q1 2025, highlighting its revenue generation and asset base, which are crucial for investors and stakeholders.

Risk Assessment

Risk Level: medium — The company has minimal revenue and a significant cash burn, indicating a high reliance on future funding or product success.

Key Numbers

Key Players & Entities

FAQ

What was NRX Pharmaceuticals' revenue for the quarter ending March 31, 2025?

NRX Pharmaceuticals reported $0.001 in revenue for the quarter ending March 31, 2025.

How much cash and cash equivalents did NRX Pharmaceuticals have as of March 31, 2025?

As of March 31, 2025, NRX Pharmaceuticals had $17,120,120 in cash and cash equivalents.

What were the total assets of NRX Pharmaceuticals on March 31, 2025?

The total assets of NRX Pharmaceuticals on March 31, 2025, were $14,591,505.

What is the former name of NRX Pharmaceuticals?

The former name of NRX Pharmaceuticals was Big Rock Partners Acquisition Corp., with a name change date of October 12, 2017.

How many shares of common stock were authorized as of March 31, 2025?

As of March 31, 2025, 50,000,000 shares of common stock were authorized.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding NRX Pharmaceuticals, Inc. (NRXPW).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing